Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Grappo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial

作者：Gallamini Andrea^*; Zaja Francesco; Patti Caterina; Billio Atto; Specchia Maria Rosaria; Tucci Alessandra; Levis Alessandro; Manna Annunziata; Secondo Vicenzo; Rigacci Luigi; Pinto Antonello; Iannitto Emilio; Zoli Valerio; Torchio Pierfederico; Pileri Stefano; Tarella Corrado

来源：Blood, 2007, 110(7): 2316-2323.

DOI：10.1182/blood-2007-02-074641

To evaluate in a prospective multicenter trial the feasibility and clinical efficacy of the combination of alemtuzumab (Campath-1 H) with the cyclophosphamide/doxorubicin/ vincristine/prednisone (CHOP) regimen (CHOP-C) as the primary treatment for patients with peripheral T-cell lymphoma (PTCL), between January 2003 and December 2005, 24 consecutive patients with PTCL entered the study and received 8 CHOP courses. Alemtuzumab was added at 30 mg subcutaneously at day -1 initially to the first 4 courses (4 patients), and then to all 8 courses (20 patients). Complete remission (CR) was achieved in 17 (71%), patients, 1 had partial remission, and 6 had stable/ progressive disease. At a median follow-up of 16 months (range, 5-42 months), 14 patients were alive, 9 had died from progressive disease, and 1 had died from pneumonia at day +198 while in CR. So far, 13 are disease-free, with an overall median duration of response of 11 months. The most frequent side effects were grade 4 neutropenia and cytomegalovirus (CMV) reactivation. Major infections were Jacob-Creutzfeidt (J-C) virus reactivation, pulmonary invasive aspergillosis, Staphylococcus sepsis, and pneumonia. This study shows that CHOP-C: (1) is a feasible chemoimmunotherapy regimen; (2) is effective in PTCL with a high rate of CR achievement; and (3) is associated with mostly manageable infectious complications.

• 出版日期2007-10-1